Theradaptive
Revolutionizing the field of therapeutic delivery with a pipeline of first-in-class and best-in-class products that address an $80B global market.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
Theradaptive is a biotechnology company focused on developing advanced therapeutic delivery systems to improve the efficacy and safety of treatments. The company specializes in creating material binding variants of recombinant proteins for use in a variety of clinical indications, including spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics. By enhancing the precision of therapeutic delivery, Theradaptive aims to reduce off-target side effects and improve patient outcomes.
Theradaptive serves healthcare providers, medical institutions, and pharmaceutical companies operating in the biotechnology and medical sectors. The company’s business model revolves around research and development, clinical trials, and partnerships with other medical and pharmaceutical entities. Revenue is generated through licensing agreements, product sales, and collaborative research funding.
Keywords: biotechnology, therapeutic delivery, recombinant proteins, spinal fusion, orthopedics, soft tissue repair, targeted chemotherapeutics, clinical applications, precision medicine, healthcare innovation.